Evozyne, LLC, founded in 2020 and headquartered in Chicago, Illinois, USA, is a company focusing on the generation of therapeutic discovery and drug development artificial intelligence Company.
Evozyne Encyclopedia of US Stocks
Evozyne specializes in protein design and molecular scale Biotechnology Company Its mission is to release the potential of new proteins by completely changing protein design to solve complex human and social challenges.
Evozyne is committed to manufacturing new proteins to address the long-term challenges of therapeutic development. By improving the performance of proteins to an unprecedented level, Evozyne has provided solutions on a commercial scale, paving the way for new products and contributing to a healthier world.
Evozyne technology:
Evozyne uses evolutionary deep learning to simulate millions of years of evolution in the laboratory. Proteins make living things work. Evozyne's mission is to create new proteins that solve key problems. In order to achieve this goal, the company turned to the theory of evolution for guidance and found a set of revolutionary principles to explain the function of proteins. Evozyne uses this knowledge to produce adaptive, high-performance proteins to address long-term therapeutic challenges.
Evozyne Products:
Evozyne's products are high-performance, adaptive proteins with extremely advanced functions. The company is looking for treatment methods that can change the life of patients and may cure incurable diseases.
Evozyne Financing Encyclopedia
In April 2020, Evozyne received $9.2 million in venture capital.
In April 2021, Evozyne completed round A financing of US $54.2 million.
In September 2023, Evozyne will complete Fidelity and OrbiMed Round B financing of $81 million led by investors, Valor Equity Partners 、 NVentures And Paragon Biosciences.
Evozyne US equity investment
Unlisted company , official website of the company, waiting for Evozyne IPO Listing.
